Clinical Trial Update: Evaluation of the Inhaled TQC3721 Suspension in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating inhaled TQC3721 suspension for moderate-to-severe chronic obstructive pulmonary disease is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• TQC3721 Suspension

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 3 | Status: NOT_YET_RECRUITING